XyloCor Therapeutics has completed a $67.5 million Series B financing to support a Phase IIb clinical trial (EXACT‑2) of XC001 (encoberminogene rezmadenovec) in refractory angina.  The trial will use a new non‑surgical method of endocardial administration via a novel injection catheter.   The financing will also fund a Phase II trial of XC001 as an adjunctive […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!